Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Key Highlights
- ➤Admilparant 60 mg met Phase 3 primary endpoint, significantly improving Week 52 FVC versus placebo
- ➤Admilparant 120 mg slowed FVC decline but failed to reach statistical significance
- ➤Admilparant showed favorable safety, with low discontinuations due to adverse events
- ➤Bristol Myers Squibb plans regulatory submissions after comprehensive ALOFT-IPF data evaluation
- ➤ALOFT-PPF topline results are anticipated in early 2027
Expert Statements
Cristian Massacesi, MD, Executive vice president, chief medical officer and head of development, Bristol Myers Squibb
“Taken together, these topline data reinforce the profile of admilparant as a promising, clinically meaningful investigational therapy for IPF – one that reflects the innovation of targeting the LPA(1) pathway as a first-in-class approach”
Fernando Martinez, MD, Chair of the ALOFT program clinical steering committee and the Joseph D. Early Chair in Biomedical Research, interim chair and professor of medicine at UMass Chan Medical School
“IPF remains one of the most complex and challenging lung diseases to treat, with unpredictable progression, irreversible scarring and a profound impact on patients’ daily lives”
Fernando Martinez, MD, Chair of the ALOFT program clinical steering committee and the Joseph D. Early Chair in Biomedical Research, interim chair and professor of medicine at UMass Chan Medical School
“These admilparant results represent an important advancement as there remains a need for therapies that are both effective and tolerable for patients living with IPF.”
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
In the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placebo
Get started
Create a free account to read the full story.